

CURRICULUM VITAE

John Douglas Hudson, M.D.

FutureSearch Trials of Neurology and Sleep Lab
5508 Parkcrest Drive, Suites 300 & 310
Austin, TX 78731
Tel: (512) 380-9925

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

EDUCATION:

1958 Bachelor of Arts, Major: Chemistry
Texas Tech University, Lubbock, TX

1960 Masters Business Administration
Northwestern University, Chicago, IL

1963 Doctor of Medicine
University of Texas Medical Branch, Galveston, TX

INTERNSHIPS AND RESIDENCIES:

1959-1960 Administrative Residency
Brackenridge Hospital, Austin, Texas

1963-1964 Medical Internship
Methodist Hospital, Dallas, Texas

1964-1967 Neurology Residency
University of Iowa, Iowa City, Iowa

CERTIFICATIONS:

American Board of Neurology (Fellow), 1979

American Board of Sleep Medicine (Diplomat), 1999

American Academy of Sleep Medicine (Fellow)

American Society of Neuro Rehabilitation (Diplomat), 1997

Texas Medical Board License Number D0915

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2001 – Present
FutureSearch Trials, Austin, TX

Founder and President, 2000 - Present
Sleep Medicine Consultants, Austin, TX

Hospital Staff, 1999 – Present
Brackenridge, St. David's, Seton, Texas NeuroRehab Center, Heart Hospital of Austin

Private Practice, Neurology, 1967 – Present
Austin, TX

Founder, 1970
Austin EEG and Neuroscience Laboratory, Austin, TX

Founder, 1970
Austin Neurological Clinic, Austin, TX

Austin Neuro Diagnostics, 1975
Austin, TX

Medical Director
Texas State University Sleep Lab, San Marcos, TX
REM Sleep Center, Austin, TX

CLINICAL RESEARCH EXPERIENCE:

Carpal Tunnel Syndrome • Diabetic Neuropathy • Epilepsy • Fibromyalgia
Insomnia • Low Back Pain • Migraine • Neurological Disorders
Obstructive Sleep Apnea/Hypopnea Syndrome • Osteoarthritis • Osteoporosis
Obstructive Pulmonary Disease • Other Sleep Disorders • Pain • Parkinson's Disease
Post Herpetic Neuralgia • Restless Legs Syndrome (RLS) • Rheumatoid Arthritis
Tinnitus • Traumatic Brain Injury

ADDITIONAL TREATMENT EXPERIENCE:

Alzheimer's Disease • Hypertension • Hyperlipidemia • Stroke and Stroke Prevention

CLINICAL TRIAL EXPERIENCE:

Phase I Insomnia

A Multicenter, Open-label Study to Determine the Effects of XXX on Sleep in Healthy Subjects

Epilepsy

A Prospective Randomized 12-week Controlled Study of Visual Field Change in Subjects with Partial Seizures Receiving XXX or Placebo

A Phase III, 12-month, Open-label Study Evaluating the Safety and Tolerability of Flexible Doses of XXX as Adjunctive Therapy in Pediatric Patients Ages 1 month to 16 years with Partial Onset Seizures and Pediatric and Adult Patients Ages 5 to 65 years with Primary Generalized Tonic-Clonic Seizures

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of XXX Controlled Release Formulation as Adjunctive Therapy in Adult Subjects with Partial onset Seizures

A Multi-center, Open-Label Study to Assess the Efficacy of as First Add-on Treatment in Adult Patients (17-65) with Partial-Onset Seizures. This Phase III b/IV Study will Assess Two Groups of Epilepsy Patients: Patients who are Not Responding to Monotherapy Anti-Epileptic Drug (AED) Treatment (Diagnosis \leq 12 Months); OR Patients who Have Not Responded to More Than Two Treatments (Diagnosis \geq 5 Years)

A Randomized, Double-Blind, Parallel-Group, Multi-center Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

A 9-11 Week Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effects of Adjunctive XXX on the Sleep Architecture of Adult Subject (18 – 45 Years of Age) with Partial Onset Epilepsy Receiving a First Generation Anti-Epileptic Drug

Insomnia

A 12-Month, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of XXX as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Polysomnography Study to Evaluate the Safety and Efficacy of XXX in [adults and] Elderly Patients with Primary Insomnia

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-center Outpatient Trial of XXX in Adults with Nonrestorative Sleep

A Phase III, Efficacy and Safety of XXX in Insomnia Characterized by Sleep Maintenance Difficulties: A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Polysomnography Study

A Randomized, Double-Blind, Placebo-Controlled Subjective Study to Assess the Efficacy of XXX in Patients with Primary Insomnia characterized by Difficulty in Maintaining Sleep

A Phase II Randomized, Double-Blind, Placebo-and Active-Comparator-Controlled Study of the Safety and Efficacy of XXX in Outpatients with Insomnia

A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Sleep Laboratory Efficacy and Safety Study with XXX in Elderly Subjects with Chronic Primary Insomnia

A Fifty-Two Week Open Label Extension Trial, to Evaluate the Efficacy and Safety of XXX Trial in Outpatients with Chronic Primary Insomnia who Completed Clinical Trial

A Multi-center Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of XXX in the Treatment of Primary Insomnia

An Efficacy and Safety of XXX on Sleep Maintenance Insomnia with a Sub-Study of the Effect of XXX on Stable Type II Diabetes Mellitus: A One Year, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study

A Six Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial with XXX Trial in Patients with Chronic Primary Insomnia

A Randomized, Double Blind, Placebo-Controlled Study to Determine the Long-Term Efficacy and Safety of XXX in Adults with Chronic Insomnia
The Safety and Efficacy of XXX Taken in Combination with XXX

A 28-Day, Polysomnographic and Subjective Assessment of XXX for the Treatment of Primary Insomnia: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial

A Multi-center, Randomized, Double Blind, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of XXX and Matching Placebo in Healthy Male and Female Subjects with Induced Transient Insomnia

CLINICAL TRIAL EXPERIENCE (continued):

A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-center Proof-of-Concept Study to Evaluate the Safety and Efficacy of XXX Taken in Combination with XXX for the Treatment of Subjects with Chronic Insomnia

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Long-Term Efficacy and Safety of XXX in Adults with Chronic Insomnia

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effects of XXX on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Nonelderly Subjects with Primary Insomnia

An Efficacy and Safety of XXX on Sleep Maintenance Insomnia: A 12-Week Multi-center, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Treatment Phase Extension with XXX for 40 Weeks Period

A Randomized, Double-Blind, Placebo-Controlled, Three-Way Cross-Over Study of XXX in Patients with Insomnia

A Randomized Double-Blind Comparison of XXX, XXX, and Placebo in the Treatment of Patients with Primary Insomnia

An Evaluation of the Long-Term Efficacy and Safety of XXX Compared to Placebo, When Both Are Administered Over a Long-Term Period "As Needed," in Patients with Chronic Primary Insomnia. (A Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multi-center, Phase IIIb Clinical Study)

A Four-Week, Multi-center, Phase IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose, Parallel-Group Study of the Efficacy and Safety of XXX Tablets in the Treatment of Sleep Maintenance Insomnia

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-center, Study of XXX in Healthy Adult Volunteers Participating in a Four-Hour Phase Advance Model of Transient Insomnia

A Randomized, Four-Way Cross-Over, Double-Blind, Placebo-Controlled, Multi-center Dose-Finding Trial with Three Dosages of XXX in Patients with Primary Insomnia

A Six-Month, Chronic Efficacy and Safety Study of XXX in Adult Subjects with Primary Insomnia: A Randomized Double-Blind, Placebo-Controlled Study

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized Double-Blind, Placebo-Controlled Paralled, Two-Week Objective Efficacy and Safety Study of XXX in Elderly Subjects with Primary Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of XXX in Adults with Chronic Insomnia

A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long Term Administration of XXX in Subjects with Chronic Insomnia

A North American, Four-Week, Multi-center, Phase IIB Double-Blind, Placebo-Controlled, Randomized, Multiple Dose, Parallel-Group Study of the Efficacy and Safety of XXX Tablets in the Treatment of Sleep Maintenance Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of A Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXX in Adult Patients with Primary Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

A Phase III, Open-Label, Outpatient, Extension Study to Assess the Long-Term Safety of a Modified Release Formulation of XXX in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties

A Phase III, Randomized, Double-Blind Placebo-Controlled, PSG Plus Outpatient Study to Determine the Safety and Efficacy of XXX in Adults with Chronic Insomnia

A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long Term Administration of XXX in Subjects with Chronic Insomnia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Long-Term Safety and Efficacy of Two Dose Levels of XXX in Adult Patients with Primary Insomnia

The Comparison of Efficacy and Safety of XXX and Placebo in Patients with Primary Insomnia. A Double Blind, Randomized, Placebo-Controlled, Parallel Group Study

CLINICAL TRIAL EXPERIENCE (continued):

Fibromyalgia

A Phase IIIb Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study of XXX in the Treatment of Fibromyalgia with Concurrent Antidepressant Therapy for Comorbid Depression

A Comprehensive Evaluation of Impacts and Possible Outcome Assessments

A Phase III Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Study of Once Daily Controlled Release XXX in the Treatment of Patients with Fibromyalgia

A Phase II, Multicenter, Open-label, 52-Week Extension Study to Evaluate the Safety and Efficacy of XXX in Pediatric Patients With Primary Fibromyalgia

A Phase II, Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of XXX in Pediatric Patients With Primary Fibromyalgia

A Safety and Tolerability Study Comparing XXX Given as an Oral Solution to a Single-Blinded Combination of Oral Tablets Plus Oral Solution in Subjects with Fibromyalgia

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of XXX to Evaluate Responsiveness of, and Estimate the Clinically Important Difference in, a Novel Fatigue Tool in Subjects with Fibromyalgia

The Safety and Tolerability Study Comparing XXX Given as an Oral Solution to a Single-Blinded Combination of Oral Tablets Plus Oral Solution in Subjects with Fibromyalgia

A Randomized Evaluation of a Low Frequency Investigational Device Employing Neuromodulation Therapy in Patients with Fibromyalgia: A Double-Blind, Placebo-Controlled Trial

A Multi-center, Randomized, Double-Blind, XXX-Referenced, Placebo-Controlled, Parallel-Group, Adaptive Design Study of XXX in Adult Female Outpatients with Fibromyalgia Syndrome

A Multi-center, Multiple Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of XXX in Female Patients with Fibromyalgia Syndrome

A Six-Month Open Label Extension Study of the Long-Term Safety of the XXX in Outpatient with Fibromyalgia Syndrome

CLINICAL TRIAL EXPERIENCE (continued):

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive-Design, Efficacy, Safety and Tolerability Study of 4 Fixed Oral Doses of XXX in Adult Outpatients with Fibromyalgia Syndrome

Narcolepsy or Obstructive Sleep Apnea (OSA)

A Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of XXX Treatment in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy

A Short-Term (Eight-Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes with XXX Treatment for Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

A Randomized Phase II, Double-Blind, Placebo-Controlled, Multi-center Crossover Study of XXX as a Daily Treatment for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy

A Consumer Preference Study of the XXX All-in-One Positive Airway Pressure System on adult patients with Obstructive Sleep Apnea (OSA)

A One-Year Open Label, Flexible Dosage Extension Study to Assess the Safety and Continued Effectiveness of XXX Treatment in Children and Adolescents with Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome

A Phase III, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of XXX Treatment in Children and Adolescents with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX at a Target Dosage of XXX as Treatment for Adults with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome with Comorbid Major Depressive Disorder or Dysthymic Disorder

A Short-Term (Eight-Week) Open-Label Study, Followed by a Long-Term Evaluation, to Assess Patient-Reported Outcomes with XXX Treatment for Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX as Treatment for Adults with Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome

CLINICAL TRIAL EXPERIENCE (continued):

A 12-Month, Open-Label, Flexible-Dosage Extension Study of the Safety and Efficacy of XXX in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

Other Sleep Disorders

A Four-week, Double-blind, Placebo-controlled, Randomized, Cross-over Study of the Safety and Efficacy of XXX in the Treatment of Excessive Daytime Sleepiness

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of XXX Treatment (150 mg) in Improving Clinical Condition Late in the Shift and in Improving Functional and Patient-Reported Outcomes in Adult Patients With Excessive Sleepiness Associated with Shift Work Disorder

A 12 week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage, Study to Evaluate the Efficacy and Safety of XXX as Treatment for Patients with Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury

A Randomized, Double-Blind, Placebo-Controlled, Parallel, Proof of Concept Study to Evaluate the Effectiveness of XXX to Advance the Timing of Sleep in Individuals with Delayed Sleep Phase Syndrome (DSPS)

A Phase III Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 12 Weeks of Study Drug XXX as Treatment for Adults with Excessive Sleepiness Associated with Chronic Shift Work Sleep Disorder (SWSD)

Pain

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of XXX for Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of XXX 20MG and 120MG Twice Daily for 4 Weeks in Patients with Chronic Peripheral Neuropathic Pain

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXX controlled-release Tablets to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to XXX Controlled-release Tablets) in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

CLINICAL TRIAL EXPERIENCE (continued):

An Open Label, Safety and Tolerability Study of Multi-Layer, Extended-Release Tablets of XXX in the Treatment of Patients with Moderate to Severe Acute Pain of Up to 30 Days, of Non-Malignant Origin

A Phase IV, Open Label, Study of Safety and Effectiveness of XXX Tablets in the Treatment of Patients with Postherpetic Neuralgia in Clinical Practice

A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of XXX Tablets Once-daily in Subjects with Moderate to Severe Chronic Low Back Pain

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXX for the Treatment of Opioid-induced Constipation (OIC) in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy

Qualitative Study to Assess the Content Validity of the Modified Insomnia Severity Index (ISI) in Chronic Pain Patients

A Phase IIb Double blind Randomized Placebo controlled, Dose-ranging Trial of XXX for the Acute Treatment of Migraine

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXX controlled-release Tablets to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to XXX) in Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

A Open-label, Multicenter Study to Assess the Long -term Safety of XXX Tablets 20 to 120 mg Once-daily in Subjects with Moderate to Severe Chronic Nonmalignant and Non-neuropathic Pain

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of XXX Controlled-release Tablets Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy

Validation of Short Treatment Satisfaction Questionnaire for Use in Neuropathic Pain Patients Treated with XXX

A Phase II, 52-week, Open-label, Long-term Treatment Evaluation of the Safety and Efficacy of XXX in subjects with moderate to severe Chronic Pain

A Multicenter, Double-blind, Placebo-controlled, Cross-over Study of the Safety and Efficacy of XXX in Patients with Post-herpetic Neuralgia (PHN)

CLINICAL TRIAL EXPERIENCE (continued):

A Phase 4 Multi-center, Primary Care-Based, Open-Label Study to Assess the Success of Converting Opioid-Experienced Patients, with Chronic, Moderate to Severe Pain, to XXX Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion

A Phase III, Multicenter, 12-Month, Open-Label, Single-Arm, Safety Study of XXX and XXX Extended-Release Capsules in Subjects With Moderate to Severe Chronic Non-cancer Pain

A 12-week placebo-controlled, double-blind, randomized withdrawal study to evaluate the efficacy and safety of XXX in subjects with moderate to severe chronic low back pain.

A Multi-center, Double-Blind, Randomized, Placebo-controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of XXX in Patients with Postherpetic Neuralgia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Two-Period Cross-Over Study to Evaluate the Safety Tolerability, Preliminary Efficacy and Systemic Exposure of XXX in Patients with Post Herpetic Neuralgia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Two-Treatment, Two-Period Cross-Over Study to Evaluate the Safety Tolerability, Preliminary Efficacy and Systemic Exposure of Topical XXX in Patients with Post Herpetic Neuralgia

A Randomized, Double-Blind, Placebo-Controlled, Multi-center Trial with an Enriched Study Design to Assess the Efficacy and Safety of XXX Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Chronic Low Back Pain

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Study of the Safety and Efficacy of Subcutaneously Administered XXX in Patients with Osteoarthritis of the Knee

A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of XXX in Patients with Post-herpetic Neuralgia

A Randomized, Double-Blind, Placebo-Controlled with Open-label Run-in Assessing Efficacy, Tolerability, Safety of XXX Compared to Placebo in Opioid-Naïve Subjects with Moderate to Severe, Chronic Pain Due to OA of the Knee

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of XXX in Patients with Osteoarthritis of the Knee

CLINICAL TRIAL EXPERIENCE (continued):

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXX in Patients with Chronic Low Back Pain

A Phase IIb, Randomized, Double-Blind, Two-Arm, Multi-center, Placebo-Controlled, Study to Assess the Efficacy and Safety of XXX in Subjects with Moderate to Severe Chronic Low Back Pain (CLBP)

A Phase IIa, Randomized, Blinded, Placebo- and Active-controlled, 2-Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of XXX in Subjects with Post herpetic Neuralgia

A Safety, Tolerability, and Efficacy Study of XXX in the Treatment of Acute Migraine Headache

A Randomized, center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

An Open-Label 52-Week Safety Study of SR XXX in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

A Double-Blind, Randomized, Parallel-Design, Placebo-Controlled, Multi-center, Study of Two Doses of XXX in Adult Outpatients with Pain Associated with Chronic Diabetic Neuropathy

A Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Effect of XXX at Two Doses for 24-Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients with Mild Diabetic Peripheral Neuropathy

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Diabetic Painful Neuropathy and Small Fiber Neuropathy Associated with Impaired Glucose Tolerance Followed by a Double-Blind Safety Extension and an Open Label Safety Extension The Investigation of the Efficacy and Pharmacokinetics of XXX in Subjects with Neuropathic Pain Associated with Post-Herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to XXX Treatment

A Phase III Multi-center, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study of the Safety and Efficacy of XXX Tablets in the Treatment of Patients with Post-herpetic Neuralgia” (“Study”) in accordance with Sponsor’s Protocol

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral Medication TID, Versus Placebo in the Treatment of Post Herpetic Neuralgia

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Once-Daily XXX Extended Release Tablets in the Treatment of Patients with Post-herpetic Neuralgia

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the XXX Patch 5% with Placebo in Patients with Pain from Carpal Tunnel Syndrome

A Phase II Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Subjects with Moderate to Severe Chronic Low Back Pain

A Phase II Randomized, Double-Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-center, Parallel Group Study of the Analgesic Effect of XXX in Adult Patients with Chronic Low Back Pain

A Phase III, Randomized, Double-Blind, Placebo- and Active-Control, Parallel-Arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of XXX Extended-Release (ER) in Patients with Moderate to Severe Chronic Low Back Pain

A Phase III Multi-center, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Run-In to Assess the Efficacy, Tolerability, and Safety of XXX or XXX Compared to Placebo in Opioid-Naïve Subjects with Moderate to Severe, Chronic Pain Due to Osteoarthritis of the Knee

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Moderate to Severe, Chronic Knee or Hip Pain From Osteoarthritis

Parkinson's Disease

A 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of XXX in Subjects With Moderate to Severe Parkinson's Disease

A Phase III, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Moderate to Severe Parkinson's Disease

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of XXX Agonist Versus Placebo in Patients with Early Parkinson's Disease

An Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response in Patients with Parkinson's Disease

The Safety and Efficacy of XXX in the Treatment of Patients with Psychosis Associated with Parkinson's Disease

CLINICAL TRIAL EXPERIENCE (continued):

A Phase IIIb, Randomized, Double-Blind, Double-Dummy XXX-Controlled, Parallel Group Study of Two Years Treatment with XXX or XXX as Adjunctive Therapy in Patients with Parkinson's Disease Not Optimally Controlled on XXX

Restless Legs Syndrome

A Randomized, Double-blind, Placebo-controlled, Safety and Efficacy Study of XXX in the Treatment of Moderate to Severe Restless Legs Syndrome (RLS)

A Multicenter, Open-label, 2-group, Dose Escalation Study of Monotherapy Administration of XXX in Pediatric Subjects with Idiopathic Restless Legs Syndrome

A Phase II, Open-label, Long-term, Follow-up Study to determine the Safety, Tolerability and Efficacy of XXX as Monotherapy in Adolescents with Restless Legs Syndrome

A Fixed Dose Randomized, Double-Blind, 12-week Study of XXX Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome

A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multi-center Polysomnography Study of XXX and XXX in Adults with Restless Legs Syndrome

A Fixed-dose, Randomized, 12-Week Placebo-Controlled, 52-week Comparator-Controlled, Double-Blind Study to Assess the Rates of Augmentation, Efficacy and Safety of XXX and XXX in Subjects with Moderate to Severe Idiopathic RLS

An Open-Labeled, 52-Week Extension Study Assessing XXX Safety and Efficacy in Patients with Restless Legs Syndrome

A Phase II, Double Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-center, Study to Evaluate the Efficacy and Safety of XXX in Subjects with Restless Legs Syndrome (RLS)

A Four-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From XXX Immediate Release (IR) to XXX Extended Release (XR) Formulation in Patients with Restless Legs Syndrome (RLS)

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of XXX in Subjects with Idiopathic Restless Legs Syndrome

An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal XXX in Subjects with Idiopathic Restles Legs Syndrome

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in Patients with Restless Legs Syndrome

A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of XXX in Patients Suffering From Restless Legs Syndrome (RLS)

A 12-Week Double-Blind, Placebo Controlled Study to Assess the Tolerability, Efficacy and Safety of XXX Dosed PRN in Subjects with Restless Legs Syndrome (RLS) who Respond to Open-Label Treatment with XXX

A 12-Week, Double-Blind, Placebo Controlled, Twice Daily Dosing Study to Assess the Efficacy and Safety of XXX in Patients Suffering From Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Other Indications

A Phase IV Safety and Efficacy Study of Inhaled XXX Combination versus Inhaled XXX in the Treatment of Adolescent and Adult Subjects with Asthma

A Placebo-Controlled Randomized Withdrawal Evaluation Of The Efficacy And Safety of XXX In Subjects With Spasticity Due To Multiple Sclerosis

Open Label Long Term Safety Study: An Open-Label Study to Assess the Long-Term Safety of XXX in Patients with Opioid-Induced Constipation (OIC)

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

A Phase III, Six-month Randomized, Active Comparator, Open label, Multi-center Study to Evaluate Patient Outcomes, Safety and Tolerability of XXX in patients with Relapsing Remitting MS who are candidates for MS Therapy Change from previous Disease Modifying Therapy

A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXX in Subjects with Opioid-Induced Bowel Dysfunction

A Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of XXX Compared With Placebo for 12 Weeks in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the 2 XXX Doses

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of XXX in Patients with Subjective Tinnitus AND an Open-Label, Long-Term Treatment Study to Assess the Long-Term Safety and Tolerability and Efficacy of XXX in Patients with Subjective Tinnitus

A Three-Arm, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of XXX for the Treatment of Adults with Stuttering

An Eight -Week, Double Blind, Randomized, Multi-center, Flexible-Dose, Placebo Controlled Pilot Study of XXX in Patients with PDS Followed by a 52-Week Open-Label Extension

Pharmacogenomics Blood Sampling Protocol for XXX

SPEAKER'S BUREAU AND PRESENTATIONS:

Jazz Pharmaceutical National Advisory Board 2004-2010

USB Neupro Advisory Board 2009-2010

Member, Cephalon Advisory Panel, 2009-2010

Sanofi National Speaker's Bureau, 2002-2009

Forest Laboratories, Inc., 2009

Takeda, 2005-2008

Sepracor, 2003-2008

Boeringer-Ingelheim, 2002-2008

Sleep Disorders, Stroke and Heart Attack (El Paso Heart Conference 2009)

Texas Advanced Nurse Practitioner Conference, 9/2008

Atlanta School of Sleep Medicine (San Antonio), Lecturer 2006 - 2009

Sleep Disorders in Rehabilitation Setting (Brown Schools Annual Conf)

Grand Rounds, Seton Medical Center, Insomnia, 2006

Grand Rounds, Heart Hospital, Sleep Disordered Breathing, Cardiovascular & Cerebrovascular Disease, 2006

USA Today National Hotline - Sleep Disorders, Ntl. Sleep Foundation (Washington, DC 2000, 2001)

Sleep Disorders Interview, KTBC 2006, KXAN 2003

Stroke interviews, KKMJ and KVUE 1999-2001, 2006

Stroke Rehab (Puerto Rico Heart Assoc. / San Juan), 1998

SPEAKER'S BUREAU AND PRESENTATIONS (continued):

Stroke Prevention (Marble Falls, Llano, Austin, Bastrop)/Brackenridge Hospital

9/2001-11/2002

Grand Rounds Brackenridge Hospital, Austin Internal Medicine Society

Parkinson's and Music Therapy (Cleveland, Ohio), 2000

Parkinson's Disease (McAllen, HealthSouth, Parkinson's Capital Area Society)

SPECIAL HONORS:

Brown Schools Rehab Center Physician of the Year (1994)

Roger McCary Award for Physician Excellence 1997

Texas Medicine, Editorial Consultant

Seton Hospital League House, Chairman of the Board, 2001-2008

Texas Neurological Society, Past President 2000-2001

Capital Area American Heart Association, President, 2001-02, Austin, TX

Health Initiative Leader, American Heart Association, Texas, 2003

Distinguished Service Award, American Heart Association, Texas 2002

AMA Physician Recognition Award (2004-2009)

PUBLICATIONS:

Hudson, J.D. and Simpson, Cherie: "Taking Back Life", *Sleep Review*, Jan-Feb, 2007 p. 88

Hudson, J.D., Neurologic Complications of Pregnancy, G.P. 1966, 34, 159-165.

Hudson, J. D. and Winkelman, J.W. et al, A Randomized, Placebo-Controlled Polysomnography Study of Gabapentin Enacarbil in Patients with RLS pending publication, 2011

Hudson, J.D. A Randomized, Crossover Polysomnography Study of Gabapentin Enacarbil in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome and Associated Sleep Disturbance. The 62nd American Academy of Neurology Annual Meeting, April, 2010, at the Metro Toronto Convention Centre in Toronto, ON, Canada. Abstract no. 1346AAN10D1.

Hudson, J. Douglas and Simpson, C, Taking Back Life, *Sleep Review Journal*, Jan/Feb 2007, 8, 88-89.

PUBLICATIONS (continued):

Hudson, J.D., Joynt, R.J. and Pribram, H.F.W., Water Retention Following Neurological Procedures, *Arch. Neurol.* 1967, 16, 624-626.

Hudson, J.D., Pregnancy and Neurologic Disease, *G.P.* 1967, 35, 99-104.

McKee, A.P., Hudson, J.D. and Joynt, R.J., Herpes Simplex Encephalitis, *So. Med. J.*, 1968, 61, 217-235.

Pribram, J.H.W., Hudson, J.D. and Joynt, R.L., Posterior Fossa Aneurysms Presenting as Mass Lesions, *Am. J. Roent., Rad. Ther. and Nuclear Medicine* 1969 CV, 334-340.

Mejias, C.L. and Hudson, J.D. et al, Telemedicine as a Tool to Enhance Rehabilitation in Dialysis Patients, *International Symposium / Dialysis, 1998*.